A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Àlex Rovira(Centre National de la Recherche Scientifique), Jaume Sastre‐Garriga(Universitat Autònoma de Barcelona), Mar Tintoré(Vall d'Hebron Hospital Universitari), FX Aymerich(Vall d'Hebron Hospital Universitari), Cecilia Borrás(Hebron University), Luís Brieva(Hebron University), J. Porcel(Vall d'Hebron Hospital Universitari), Jordi Río(Universitat Autònoma de Barcelona), Carlos Nos(Universitat Autònoma de Barcelona)
Cited by 108
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k